SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitocco, Dario, Tartaglione, Linda, Viti, Luca, Di Leo, Mauro, Pontecorvi, Alfredo, Caputo, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179491/
https://www.ncbi.nlm.nih.gov/pubmed/32335097
http://dx.doi.org/10.1016/j.diabres.2020.108162
_version_ 1783525668622958592
author Pitocco, Dario
Tartaglione, Linda
Viti, Luca
Di Leo, Mauro
Pontecorvi, Alfredo
Caputo, Salvatore
author_facet Pitocco, Dario
Tartaglione, Linda
Viti, Luca
Di Leo, Mauro
Pontecorvi, Alfredo
Caputo, Salvatore
author_sort Pitocco, Dario
collection PubMed
description Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn’t represent a plausible approach to mitigate COVID-19.
format Online
Article
Text
id pubmed-7179491
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71794912020-04-24 SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons? Pitocco, Dario Tartaglione, Linda Viti, Luca Di Leo, Mauro Pontecorvi, Alfredo Caputo, Salvatore Diabetes Res Clin Pract Article Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn’t represent a plausible approach to mitigate COVID-19. Elsevier B.V. 2020-05 2020-04-23 /pmc/articles/PMC7179491/ /pubmed/32335097 http://dx.doi.org/10.1016/j.diabres.2020.108162 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pitocco, Dario
Tartaglione, Linda
Viti, Luca
Di Leo, Mauro
Pontecorvi, Alfredo
Caputo, Salvatore
SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
title SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
title_full SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
title_fullStr SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
title_full_unstemmed SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
title_short SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
title_sort sars-cov-2 and dpp4 inhibition: is it time to pray for janus bifrons?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179491/
https://www.ncbi.nlm.nih.gov/pubmed/32335097
http://dx.doi.org/10.1016/j.diabres.2020.108162
work_keys_str_mv AT pitoccodario sarscov2anddpp4inhibitionisittimetoprayforjanusbifrons
AT tartaglionelinda sarscov2anddpp4inhibitionisittimetoprayforjanusbifrons
AT vitiluca sarscov2anddpp4inhibitionisittimetoprayforjanusbifrons
AT dileomauro sarscov2anddpp4inhibitionisittimetoprayforjanusbifrons
AT pontecorvialfredo sarscov2anddpp4inhibitionisittimetoprayforjanusbifrons
AT caputosalvatore sarscov2anddpp4inhibitionisittimetoprayforjanusbifrons

Ejemplares similares